Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus appoints Claudia Fromond as new Director of R&D
    10 March, by Emmanuelle BETTENDORF

    We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.
    Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.
    “Claudia has a proven track record of successfully (…)

  • Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
    22 April 2024, by Emmanuelle BETTENDORF

    Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
    The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

  • Meet Vect-Horus at Deeptech in Glioblastoma Symposium
    13 January, by Emmanuelle BETTENDORF

    Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.
    Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov’nCare , with the discussion moderated by Professor Ahmed Idbaih .
    It takes place (…)

  • How blood–brain barrier technology is unleashing CNS therapies
    19 September 2025, by Emmanuelle BETTENDORF

    Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
    It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
    It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

  • Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
    12 October 2023, by Emmanuelle BETTENDORF

    Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
    We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)

  • Vect-Horus will present at Delivery of Macromolecules, June 8, 2022
    30 May 2022, by Elodie DORMES

    Guillaume JACQUOT, Head of Intracellular Trafficking & Translational Research, will give a talk on this occasion.

  • Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
    8 July 2021, by Elodie DORMES

    Vect-Horus and RadioMedix are pleased to announce the FDA clearance of eIND application to evaluate 68Ga-RMX-VH for the diagnostic of GBM.

  • Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
    Using in vivo (…)

  • Our latest research article is now available on bioRxiv and medRxiv
    11 July 2025, by Emmanuelle BETTENDORF

    In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.
    We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for (…)

  • 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
    12 April 2022, by Elodie DORMES

    Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.